Preliminary test of group acceptance and commitment therapy on obsessive-compulsive disorder for patients on optimal dose of selective serotonin reuptake inhibitors

Farzaneh Rohani, Morad Rasouli-Azad, Michael P. Twohig, Fatemeh Sadat Ghoreishi, Eric B. Lee, Hossein Akbari

ARTICLE INFO

Keywords:
- Obsessive-compulsive disorder
- Acceptance and commitment therapy
- Selective serotonin reuptake inhibitors
- Depression
- Ruminative thought
- Psychological flexibility

ABSTRACT

The aim of this study was to investigate the effects of adding group acceptance and commitment therapy (ACT) to adults diagnosed with obsessive compulsive disorder (OCD) who were already on an optimal dose of selective serotonin reuptake inhibitors (SSRIs).

Forty-six Iranian women, on SSRIs, were randomized to group ACT + SSRI or continued SSRI conditions. SSRIs dosages stayed stable during the study. Assessments included the Structured Clinical Interview (SCID-I), Yale-Brown Obsessive-Compulsive Scale Self report (Y-BOCS-SR), Beck Depression Inventory-II (BDI-II), Ruminative Response Scale (RRS), and Acceptance and Action Questionnaire (AAQ-II). The results showed significant reductions on the Y-BOCS-SR and BDI-II in both conditions at posttreatment with significantly greater reductions in the ACT + SSRI condition at follow-up. The RRS and AAQ-II saw significant improvements in the ACT + SSRI condition at posttreatment and follow-up compared to the SSRI condition. Results provide cross-cultural support for group ACT as a treatment for OCD and as a successful adjunct to SSRI treatment.

1. Introduction

Obsessive-Compulsive Disorder (OCD) is a debilitating condition for many individuals. It involves recurrent obsessions that are quelled through recurrent compulsive actions. This pattern of behavior often negatively affects quality of life (Cicek, Cicek, Kayhan, Uguz, & Kaya, 2013). Selective Serotonin Reuptake Inhibitors (SSRIs) are effective pharmacological treatments for OCD (Soomro, Altiman, Rajagopal, & Oakley Browne, 2008). Nevertheless, meta-analyses indicate that behavioral therapies and behavioral therapies plus SSRIs are more effective than SSRIs alone (Romanelli, Wu, Gamba, Mojtabai, & Segal, 2014). Behavioral therapies that include exposure and response prevention (ERP) with or without an emphasis on cognitive processes are the most supported treatments for OCD (Olatunji, Davis, Powers, & Smits, 2013). In addition, Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, & Wilson, 2012), a modern version of CBT, is also showing success in the treatment of OCD (Bluett, Homan, Morrison, Levin, & Twohig, 2014). There is also some evidence suggesting that ACT for anxiety or OCD works through predicted processes of change (Arch, Wolitzky-Taylor, Efert, & Craske, 2012; Twohig, Vilardaga, Levin, & Hayes, 2015; Wolitzky-Taylor, Arch, Rosenfeld, & Craske, 2012). Thus, ACT for OCD continues to be worthy of further study.

A relationship between OCD and psychological flexibility, the key process of change in ACT, has been demonstrated with a meta-analysis finding a correlation of $r = .36$ between psychological flexibility and OCD severity. Additionally, data from a handful of studies has shown associations between improved psychological flexibility and OCD severity (see Bluett et al., 2014; Haaland et al., 2017). In the largest western trial of ACT for OCD to date, eight sessions of ACT, without in-session exposure exercises, was compared to progressive muscle relaxation (Twohig et al., 2010). Results showed that ACT was more effective than the control condition, with 46–56% (depending on analysis) of participants responding at posttreatment and 46–66% at follow up, compared to 13–18% at posttreatment and 16–18% at follow up for the control condition. Much of the research on ACT for OCD has occurred within one research group, limiting the generalizability of the results. However, recently, multiple researchers out of Iran have
systematically studied ACT for OCD in their country.

The work in Iran—by multiple research groups—started with the treatment of five adults with OCD using 10 individual sessions of ACT (Izadi, Asgari, Neshatdust, & Abedi, 2012). Individual tracking of data showed notable decreases in compulsions for all five participants and average scores on the Yale Brown Obsessive Compulsive Inventory (Y-BOCS, Goodman et al., 1989) were 30 at pre, 15 at post, and 15 at follow-up. Another small study by the same lead author included three treatment-resistant adults with OCD who were treated using 14 individual sessions of ACT (Izadi & Abedi, 2013). Individual tracking showed pretreatment, posttreatment, and follow-up scores of 32, 20, and 19.7 on the Y-BOCS. In a large randomized trial, 90 adults with OCD were randomized to one of three treatments: group ACT, clomipramine (a tricyclic antidepressant), or group ACT + clomipramine (Baghooli, Dolatshahi, Mohammadkhani, Moshagh, & Naziri, 2014). Results were as follows for pretreatment, posttreatment, and follow-up on the Y-BOCS: ACT 24, 14, and 11; clomipramine 25, 17, 14; ACT + clomipramine 25, 15, 13. Between condition effect sizes for ACT vs clomipramine were as follows, posttreatment (d = .87) and follow-up (d = .42), and the combined condition at posttreatment (d = .28) and follow-up (d = .35). This study was replicated testing a selective serotonin reuptake inhibitor (SSRI; Vakili, Gharraee, Habibi, Lavasani, & Rasoolian, 2014). Thirty-two adults were assigned to ACT, SSRI, or ACT + SSRI conditions. The ACT alone condition performed similarly to the combined condition and both demonstrated large effects over the SSRI condition (d = 1.14 and 1.28, respectively). Mean Y-BOCS scores at pretreatment and posttreatment were as follows: ACT 23 and 14, SSRI 25 and 19, and ACT + SSRI 24 and 13. Finally, sixty adults were randomized to group ACT, group time perspective therapy, group narrative therapy, or wait-list conditions (Esfahani, Kashan, Iran. All participants were at optimal target doses of SSRIs at the same levels prior to entering the study. Clients continued to systematically study ACT for OCD in their country.

To continue to investigate the utility of ACT for OCD, the following study will examine the effects of group ACT on a sample of adults who are already on a stable and optimal dose of SSRIs. The study will include data on rumination, which has demonstrated appropriate psychometric characteristics in the Iranian culture. Exclusion criteria included: (a) a BDI-II score over 29; (b) current diagnosis of bipolar disorder; (c) current psychotic episode; (d) current suicide ideation; (e) a change in SSRI dose in the last 4 weeks; (f) participation of psychological treatment in the last month; and (h) planned changes in SSRI during the 16-week trial. A psychiatrist screened 111 individuals for the study. Of those, 67 were then assessed by a clinical psychologist who excluded 21 individuals based on inclusion and exclusion criteria. This resulted in 46 participants who were randomly assigned, using a random number chart, to one of two treatment conditions. Participant mean age was 27.91 (7.26), mean duration of OCD symptoms was 20.28 (14.18) months, 45.7% had a college degree, 82.6% were unemployed and not a current student, and 47.8% were married. See Table 1 for more detailed demographic information by condition. All participants in the ACT condition completed treatment. Two participants in the ACT condition did not complete posttreatment assessments and an additional 5 did not complete follow-up. Four participants in wait-list did not complete posttreatment and an additional 3 did not complete follow-up assessments. This resulted in 32 participants with complete data for the 16-week trial. See Fig. 1 for a flowchart of participants in the study.

### Table 1

<table>
<thead>
<tr>
<th>Demographics by Treatment Condition</th>
<th>ACT + SSRI (n = 23)</th>
<th>SSRI (n = 23)</th>
<th>t or χ²</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age M (SD)</td>
<td>29.13 (7.48)</td>
<td>26.70 (6.98)</td>
<td>1.14</td>
<td>.26</td>
</tr>
<tr>
<td>Duration of OCD (months)</td>
<td>22.26 (14.27)</td>
<td>18.30 (14.12)</td>
<td></td>
<td>.35</td>
</tr>
<tr>
<td>Percent with College Degree</td>
<td>43.48%</td>
<td>57.83%</td>
<td></td>
<td>.57</td>
</tr>
<tr>
<td>Percent Married</td>
<td>52.20%</td>
<td>43.50%</td>
<td></td>
<td>.35</td>
</tr>
<tr>
<td>Percent Student or with Occupation</td>
<td>26.10%</td>
<td>8.70%</td>
<td></td>
<td>.24</td>
</tr>
</tbody>
</table>

2.2. Procedure

All participants were provided information about the two study conditions and provided informed consent to participate in the study. Eligible patients were randomly assigned to either continued SSRI management or SSRI + group ACT. All participants provided demographic information at pretreatment. In addition, an assessment battery was completed by participants at pretreatment, posttreatment, and a two-month follow-up that included the measures listed in the measures section. The SCID was only collected at pretreatment. The SCID has demonstrated appropriate psychometric characteristics in the Iranian community (Sharifi et al., 2009).

2.2.1. Continued SSRI management

The SSRI management condition consisted of the continued use of SSRIs at the same levels prior to entering the study. Clients continued to be monitored by the mental health center's psychiatrist. The dose of SSRIs did not change during the 16-week trial. No psychological treatment was provided during the trial period. Following the completion of the study, all participants in the SSRI management condition participated in the same treatment provided to those in the ACT condition.

2.2.2. Adjunctive Acceptance and Commitment Group Therapy (ACT)

The ACT condition consisted of SSRI management in addition to eight sessions of group therapy split into three small groups using an ACT treatment manual that closely followed the one used by Twohig
et al. (2010). Groups were run by an ACT-trained therapist with three years of ACT and group therapy experience. All sessions were audio-taped and were reviewed weekly by a supervisor to establish internal validity. All sessions had essential objectives that included: homework and discussion of events between session, centering exercises, metaphors and in-session exercises adapted to Iranian culture, and group discussion. Each session had a main objective based on ACT theory. In order, these included: creative hopelessness, control as the problem and introduction to acceptance, acceptance, defusion, self as context, contact with present moment, values, and committed action.

2.3. Measures

2.3.1. Yale-Brown Obsessive Compulsive Scale, Self-Report (Y-BOCS-SR; Steketee, Frost, & Bogart, 1996). The Y-BOCS-SR is a ten-item, self-report questionnaire designed to assess OCD severity. The sum of all items yields a total score (range = 0–40), with scores of 16 or greater generally denoting clinically significant levels of OCD symptoms. The scale has demonstrated good psychometric properties (Steketee et al., 1996). The Y-BOCS-SR demonstrated acceptable reliability in the current study (Cronbach’s $\alpha = .73$).

2.3.2. Beck Depression Inventory-II (BDI-II; Beck, Steer, & Brown, 1996). The BDI-II is a commonly used, self-report measure of depression. The measure consists of 21 items that are summed to produce a total score (range = 0–63). Total scores are classified into the following categories: minimal (0–13), mild (14–19), moderate (20–28), and severe (29–63) (Beck et al., 1996). The BDI-II has demonstrated good psychometric properties in Iranian samples. The alpha coefficient of the Iranian version is .86 (RAJABI & KARJO, 2013). The BDI-II demonstrated acceptable reliability in the current study (Cronbach’s $\alpha = .70$).

2.3.3. Acceptance and Action Questionnaire (AAQ-II; Bond et al., 2011). The AAQ-II is a 10-item, self-report measure of psychological flexibility. Items are summed to produce a total score (range = 10–70), with higher scores representing greater psychological flexibility. The AAQ-II has demonstrated good psychometric properties in Iranian samples. The alpha coefficient of the Iranian version is ranges from .71 to .89. (Abast, Fr, Molodi, & Zarabi, 2013). The AAQ-II demonstrated good reliability in the current study (Cronbach’s $\alpha = .81$).

2.3.4. Rumination Response Scale (RRS; Nolen-Hoeksema & Morrow, 1991). The RRS is a 22 item, self-report measure of ruminative coping responses to depressed mood and other negative symptoms. Items are summed to produce a total score (range = 22–88) with higher scores denoting higher levels of ruminative coping style. The RRS has demonstrated good psychometric properties (Wu, Zhang, Liu, Zhou, & Wei, 2015). The RSS demonstrated good reliability in the current study (Cronbach’s $\alpha = .85$).

2.4. Data analysis

Kolmogrov-Smirnov and Levene’s methods were used to test for distribution normality and equality of variances ($p < .05$) and parametric tests were utilized for statistical analysis. Demographic data were analyzed employing chi-square and independent two-sample student’s $t$-tests. Mixed models repeated measures (MMRM) analyses were utilized to examine Time by Condition and main Time and Condition effects between the ACT/SSRI and SSRI treatment conditions on outcome measures at pretreatment, posttreatment, and follow-up. This method allows for analysis of the full intent-to-treat sample and all available data points as any missing data points are modeled and included in the analysis. Missing data were modeled in this fashion for 14 participants (30.43% of the sample). All participants completed pretreatment assessment, 14 did not complete follow-up, and of those, six also did not complete posttreatment. Additional MMRM analyses were utilized to examine within- and between-group changes for each outcome measure. Analyses were also computed using repeated measures ANOVA and results were the same with the exception that the between conditions results for the Y-BOCS were significant. We are choosing to only report the intent to treat analyses using MMRM as it is the most representative way to present between group time series analyses when there is missing data.

3. Results

Independent sample $t$-test and Chi-square analysis showed no significant pretreatment differences (ps > .05) between the treatment conditions for any demographic feature, indicating homogeneity between groups. See Table 1 for detailed demographic comparison results.
Table 2 displays descriptive statistics for each variable by treatment condition at pretreatment, posttreatment, and follow-up, and Fig. 2 displays plots for the same data.

### 3.1. OCD symptom severity

MMRM analysis indicated a significant Time × Condition interaction for Y-BOCS-SR scores, $F_{(2, 33.057)} = 33.35, p < .001$, Cohen's $d = 2.01$. Between-group comparisons indicated no significant difference between the treatment conditions at posttreatment ($t(38.778) = −1.347, p = .186, d = 1.08$), however, significant differences were found at follow up ($t(35.765) = −6.583, p < .001, d = 1.53$). Within-group comparisons indicated a significant difference for the ACT/SSRI condition from pre- to posttreatment ($t(20.011) = −10.52, p < .001, d = 2.19$) and from posttreatment to follow up ($t(15.840) = −7.511, p < .001, d = 1.67$). Significant differences were also found for the SSRI condition from pre- to posttreatment ($t(18.134) = −8.315, p < .001, d = 1.90$) and from posttreatment to follow up ($t(17.132) = −4.611, p < .001, d = 1.10$). These findings indicate that both treatment conditions had a large, significant impact on reducing OCD symptoms over the treatment period that continued through follow-up; however, the ACT + SSRI condition saw significantly larger improvements at follow-up than the SSRI condition. Moreover, from baseline to follow-up there was, on average, a 71.3% improvement in Y-BOCS-SR scores in the ACT + SSRI condition compared to a 31.2% improvement in the SSRI condition.

### 3.2. Depression symptom severity

BDI-II scores demonstrated a nonsignificant Time × Condition interaction, $F_{(2, 36.810)} = 36.810, p = .089$, Cohen's $d = .53$. However, there was a significant main effect of Time, $F_{(2, 36.810)} = 99.022, p < .001, d = 3.28$, but no main effect of Condition, $F_{(1, 40.654)} = 2.820, p < .001, d = .42$. Between group comparisons indicated no significant difference between the treatment conditions at posttreatment ($t(38.778) = −1.347, p = .186, d = .42$), however, a significant difference was found at follow up ($t(37.593) = −2.411, p = .021, d = .79$). Within-group comparisons indicated a significant difference for the ACT + SSRI condition from pre- to posttreatment ($t(20.374) = −8.463, p < .001, d = 1.83$) and from posttreatment to follow up ($t(15.874) = −3.852, p < .001, d = .95$). Significant differences were also found for the SSRI condition from pre- to posttreatment ($t(19.247) = −6.454, p < .001, d = 1.42$) and from posttreatment to follow up ($t(17.659) = −4.611, p < .001, d = 1.10$). These findings indicate that both treatment conditions had a large, significant impact on reducing OCD symptoms over the treatment period that continued through follow-up; however, the ACT + SSRI condition saw significantly larger improvements at follow-up than the SSRI condition. Moreover, from baseline to follow-up there was, on average, a 71.3% improvement in Y-BOCS-SR scores in the ACT + SSRI condition compared to a 31.2% improvement in the SSRI condition.

### Table 2

Means and Standard Deviations at Pretreatment, Posttreatment, and Follow-Up by Condition.

<table>
<thead>
<tr>
<th>Measure</th>
<th>ACT + SSRI (n = 16)</th>
<th>SSRI (n = 16)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre</td>
<td>Post</td>
</tr>
<tr>
<td>YBOCS</td>
<td>22.62</td>
<td>13.50</td>
</tr>
<tr>
<td></td>
<td>(3.07)</td>
<td>(5.53)</td>
</tr>
<tr>
<td>BDI-II</td>
<td>19.31</td>
<td>9.13</td>
</tr>
<tr>
<td></td>
<td>(4.62)</td>
<td>(5.88)</td>
</tr>
<tr>
<td>RRS</td>
<td>54.06</td>
<td>34.63</td>
</tr>
<tr>
<td></td>
<td>(10.11)</td>
<td>(8.88)</td>
</tr>
<tr>
<td>AAQ-II</td>
<td>21.56</td>
<td>37.06</td>
</tr>
<tr>
<td></td>
<td>(6.13)</td>
<td>(6.58)</td>
</tr>
</tbody>
</table>

Note. MMRM analyses modeled data for participants who did not complete post and follow-up assessments. This table reports only non-missing data. YBOCS = Yale Brown Obsessive Compulsive Scale, Self Report; BDI-II = Beck Depression Inventory–II; RRS = Ruminative Response Scale; AAQ-II = Acceptance and Action Questionnaire–II.

Fig. 2. Outcome Measures at Pretreatment, Posttreatment, and Follow-Up by Condition.
two randomized trials comparing ACT plus antidepressants to antidepresants (Baghooli et al., 2014; Vakili et al., 2015), and one randomized trial comparing ACT to two active control conditions and a waitlist (Esfahani, Kjban, & Abedi, 2015). The current study adds to this support while offering some additional information. The results of all the ACT for OCD studies are supportive of ACT over comparison conditions, and achieving posttreatment and follow-up Y-BOCS-SR scores that are in acceptable ranges. This mass of data across researchers lends credibility to ACT as a method to address OCD.

This study replicates the findings that ACT + an antidepressant is more effective than the antidepressant alone (Baghooli et al., 2014; Vakili et al., 2015), while even replicating the findings with SSRIs (Vakili et al., 2015). It adds to the Vakili et al. (2015) study in that follow-up was collected. The follow-up results showed ACT continued to show gains well beyond SSRIs two months after treatment. This also add to the Iranian work showing that group ACT for OCD is effective. This is important in that it highlights that these skills can be taught to a larger group of individuals at one time. This is not surprising because many studies testing ACT are completed with groups (A-Tjaka et al., 2015). It also adds to the literature on the effects of ACT on depression and ruminitive thought.

Another notable finding is that the significance between ACT + SSRI and SSRI alone was not present until 2-month follow-up. Posttreatment scores for ACT + SSRI were fairly typical for an OCD treatment trial. The notable finding is that ACT + SSRI Y-BOCS scores were low at follow-up. It is unclear what lead to this continued drop in scores after treatment ended. While an increase between posttreatment and follow-up has not been seen in ACT for OCD, neither has this continued decrease from posttreatment to follow-up. Continued decreases like this have been seen in other ACT trials, such as work with substance use and abuse (Luoma, Kohlenberg, Hayes, & Fletcher, 2012). Unique features of this study that could positively affect follow-up and should be investigated include group treatment, female only sample, the sequencing of SSRI and ACT, or the exclusion of those with high BDI scores. The impact of these variables could be investigated in future studies.

There were several limitations in this study. First, the population of interest was limited to females. While this would be uncommon in a western society, the cultural rules and conventions in Iran make mixed-sex therapy difficult as participants are less likely to share content of obsessions with members of the opposite sex. On the one hand, it limits generalization, on the other hand, it demonstrates a cultural adaption of a therapy to a particular group. Second, the sample size was small. Combined with the Vakili study there is notable support for these general findings. Third, follow-up duration for clinical outcomes was only two months. Even though follow-up was not collected in the other ACT + SSRI trial, a much longer duration would be preferable. Repeated measurements of follow-up at 3, 6 and 12 months would be useful. Fourth, the primary outcome was measured only by self-report. While, the self-report version of the Y-BOCS has very good psychometric properties and high correlations with clinician ratings of OCD severity, a more objective measure is preferable to the self-report method used in this study and should be employed in future trials. Fifth, assessments and random assignment occurred after all participants were already on SSRIs. Thus, this study really shows the additive effects of psychotherapy to medication versus continued medication. This is still important because adding psychotherapy to medication is common in the treatment of OCD, and it is useful to know it improves outcomes over continued medication. Still, knowing the combined effects versus the stand-alone effects of medication answers additional questions, such as medication alone and the combination. Even though pretreatment Y-BOCS scores are consisted with pretreatment scores in other published outcome studies, pretreatment scores in the range of 22 is mild in terms of OCD severity as the Y-BOCS has a maximum score of 40. Sixth, participants only needed to be on stable dosages of SSRIs for 4 weeks prior to enrolling in the study. Thus, they could still be experiencing gains from the new medication during the study. Because participants were randomly assigned, the effects should have been balanced across
conditions. Finally, the obsessive-compulsive complaints of participants were mainly contamination-washing symptoms. This is partially a product of the female only participants. Sexual and religious obsessions are more prevalent in males, and females are more involved in contamination/cleaning obsessions (Mathis et al., 2011). Even with these limitations, this study notably adds to the literature on the treatment of OCD in many ways.

Authors note

This trial was supported by Kashan University of Medical Science, department of research and technology, psychiatry, and clinical research development unit of Kargarnejad hospital. We would like to thank the staffs and clients of mental health centers in Kashan for their cooperation. Support for this clinical trial was received from the Kargarnejad University of medical sciences research grant (GR-95018). This trial is registered with Iranian Registry of Clinical Trials: IRCT2016070528803N1. Please contact Mourad Rasoliazad at rasouliazad-m@kaums.ac.ir

References


